Technip Awarded a Contract for a Vaccine Plant in China.

PARIS -- Technip (PARIS:TEC) (NYSE:TKP) (ISIN:FR0000131708) has been awarded a contract by the Chengdu Institute of Biological Products (CDIBP) for the design, construction and qualification of a new production unit for Japanese encephalitis vaccines. This unit will be located in the Sichuan province of China, and will have an initial production capacity of 100 million doses per year.

The project represents a total investment of several million dollars, and is partially financed by PATH (1), an international non-profit organization, through its Japanese Encephalitis Project, which is supported by the Bill & Melinda Gates Foundation. The objective is to give CDIBP, with support from PATH, the ability to furnish World Health Organization (WHO) quality vaccines to disadvantaged populations in the Asia Pacific region.

For this contract, Technip will carry out the design and front-end engineering, project management, procurement, construction and qualification of the installations according to World Health Organization (WHO) regulations.

Technip's operations and engineering center in Paris (France) will provide the pharmaceutical and regulatory expertise in support of Technip's Shanghai center, which will carry out the studies, project management and execution.

This new project should come on stream for production in the second half of 2008.

(1) PATH works with private- and public-sector partners to create sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health

With a workforce of 21,000 people, Technip ranks among the top five corporations in the field of oil, gas and petrochemical engineering, construction and services. Headquartered in Paris, the Group is listed in New York and Paris. The Group's main operations and engineering centers and business units are located in France, Italy, Germany, the UK, Norway, Finland, the Netherlands, the USA, Brazil, Abu-Dhabi, China, India, Malaysia and Australia. In support of its activities, the Group manufactures flexible pipes and umbilicals, and builds offshore platforms in its manufacturing plants and fabrication yards in France, Brazil, the UK, the USA, Finland and Angola, and has a fleet of specialized vessels for pipeline installation and subsea construction.